Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1999-02-02
2000-11-07
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
A61K 31195
Patent
active
061437867
ABSTRACT:
A therapeutically effective amount of L-arginine, or a physiologically acceptable salt thereof, is orally administered, preferably as a food supplement in combination with a meal approved by the American Diabetes Association Inc. ("ADA"), to a person having Type II diabetes mellitus but who is not on either insulin or other medication for glycemic control. When 3 g to 15 g of L-arginine is ingested concurrently with a meal, or immediately prior to eating a meal, the L-arginine decreases the concentration of insulin generated, compared to that generated after the same meal without the L-arginine; at the same time, concentration of glucose in the person's blood is decreased, indicating that available insulin sensitizes cells so as to nearly mimic the effectiveness of normal cells in a non-diabetic person; from 3 g to 15 g of orally ingested L-arginine, by itself, produces no measurable increase in insulin secretion in a diabetic.
REFERENCES:
patent: 4053589 (1977-10-01), Gans, et al.
patent: 4234570 (1980-11-01), Kanbayashi et al.
patent: 4678670 (1987-07-01), Tomic
patent: 5000953 (1991-03-01), Ui et al.
patent: 5350766 (1994-09-01), Suarez
patent: 5428070 (1995-06-01), Cooke et al.
Efendic, et al., "Role of Glucose in Arginine-induced Insulin Release in Man," Metabolism, vol. 20, No. 6 (1971).
Efendic, et al. "Quantitative Study on the Potentiating Effect of Arginine on Glucose-induced Insulin Response in Healthy, Prediabetic, and Diabetic Subjects," Diabetes, vol. 23, pp. 161-171 (1974).
Henningsson, et al., "Arginine-induced insulin release is decreased and glucogon increased in parallel with islet NO production," Am. J. Physio., vol. 275, No. 3, pp. E500-E506 (1998).
Hollander, et al., "Glucose Modulation of Insulin and Glucagon Secretion in Nondiabetic and Diabetic Man," Diabetes, vol. 31, pp. 489-496 (1982).
Levin, et al, "Enhancement of Arginine-induced Insulin Secretion in Man by Prior Administration of Glucose," Diabetes, vol. 20, pp. 171-176 (1971).
Maccario, et al., "Effects of glucose load and/or arginine on insulin and growth hormone secretion in hyperprolactinemia and obesity," Eur. J. Endocrinol., vol. 135, pp. 205-210 (1996).
Nogowski, e tal., "Arginine Administered in Various Ways, as a Stimulator of Insulin Secretion in the Rabbit,"Horm. Metabol. Res., vol. 18, pp. 730-733 (1986).
Shimizu, et al."Effect of the enteroinsular axis on both the A- and B-cell response to arginine after oral glucose in man," Diabetologia, vol. 30, pp. 846-850 (1987).
van Haeften, et al., "Dose response Characteristics for Arginine-Stimulated Insulin Secretion in Man and Influence of Hyperglycemia," J. of Clin. Endocrinol. and Metab., vol. 69, No. 5, pp. 1059-1064 (1989).
Ward, et al., "Diminished B Cell Secretory Capacity in Patients with Noninsulin-dependent Diabetes Mellitus," vol. 74, pp. 1318-1328 (1984).
Tanner, et al., "Oxidized Low Density Lipoproteins Inhibit Relaxations of Porcine Coronary Arteries," Circulation, vol. 83, pp. 2012-2020 (1991).
Abstract 34, J. Am. Coll. Nutr. vol. 17, No. 5. (Publication date not Available).
American Diabetes Association, Inc. (1994) "Maximizing the Role of Nutrition in Diabetes Management".
Das UN, et al. (1993) "Beneficial effect of L-arginine in non-insulin dependent diabetes mellitus: a potential role for nitric oxide" Med Sci Res, vol. 21, pp. 669-670.
Gannon MC, et al. (1998) "The effects of arginine ingestion, with or without glucose, on the glucose and insulin reponse in normal subjects" Abstract 34, Am College Nutrition, Meeting.
Mitchell JA, et al. (1990) "The generation of L-arginine in endothelial cells is linked to the release of endothelium-derived relaxing factor" European J Pharm, vol. 176, pp. 253-253.
Nogowski L, et al. (1986) "Arginine, Administrated in Various Ways, as a Stimulator of Insulin Secretion in the Rabbit" Horm Metabol Res, vol 18, pp 730-733.
Paolisso G, et al. (1997) "L-Arginine But Not D-Arginine Stimulates Insulin-Mediated Glucose Uptake" Metabolism, vol. 46, No. 9, pp. 1068-1073.
Wascher, TC, et al. (1997) "Effects of low-dose L-arginine on insulin-mediated vasodilatation and insulin sensitivity" Eur J Clin Invest, vol. 27, pp. 690-695.
Arciero, PJ, et al. "Comparison of short-term diet and excercise on insulin action in individuals with abnormal glucose tolerance, " American Physiological Society, pp. 1930-1935 (1999).
Nagulesparan, M, et al. "Diminished Effect of Caloric Restriction on Control of Hyperglycemia Increasing Known Duration of Type II Diabetes Mellitus, " Journal of Clinical Endocrinolgy and Metabolism, vol. 53, No. 3, pp. 560-568 (1981).
XP-002133612, abstract.of DE 29709820 Mar. 1997.
Egberg David Curtis
Gohman Sharon Marie
Greenberg Norman Alan
Michels Lester David
Henley III Raymond
Morris Michael P.
Novartis Nutrition AG
LandOfFree
Oral arginine and insulin secretion does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oral arginine and insulin secretion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral arginine and insulin secretion will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1641610